The Institution-Based Prospective Inception Cohort Study: Design, Implementation, and Quality Assurance in Pediatric Thrombosis and Stroke Research

Abstract

The development of well-designed cohort studies in rare diseases can lead to the discovery of new risk factors and prognostic markers, enhance understanding of natural history and outcomes, and provide preliminary data for randomized controlled trials of treatment strategies. Designing a robust cohort requires substantial upfront design and planning. Ideally, a cohort study of diseased individuals follows patients prospectively from the time of diagnosis (i.e., from the disease's inception). The objective of this article is to discuss the design and implementation of an institution-based prospective inception cohort study, with applied examples in pediatric stroke and thrombosis. Furthermore, we will discuss the ongoing management and quality assurance mechanisms necessary to optimize such a study. Although the resources necessary to implement a prospective inception cohort study are large, this approach can provide critical observational evidence on natural history and prognostic factors. Following multicenter validation, its findings can inform the design and execution of much-needed randomized controlled clinical trials.

Keywords

cohort - children - quality assurance - stroke - thrombosis

• Reference

• 1 Dawber TR, Meadors GF, Moore Jr FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951; 41 (3) 279-281
• 2 Belanger CF, Hennekens CH, Rosner B, Speizer FE. The nurses' health study. Am J Nurs 1978; 78 (6) 1039-1040
• 3 Goldenberg NA, Donadini MP, Kahn SR , et al. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 2010; 95 (11) 1952-1959
• 4 University of Colorado Denver School of Medicine. Training video: clinical PTS exam example. http://www.ucdenver.edu/academics/colleges/medicalschool/centers/HemophiliaThrombosis/research/kidsdott/Pages/Sponsors%20and%20Links.aspx . Accessed August 03, 2012
• 5 Bernard TJ, Goldenberg NA, Tripputi M, Manco-Johnson MJ, Niederstadt T, Nowak-Göttl U. Anticoagulation in childhood-onset arterial ischemic stroke with non-moyamoya arteriopathy: findings from the Colorado and German (COAG) collaboration. Stroke 2009; 40 (8) 2869-2871
• 6 Bernard TJ, Fenton LZ, Apkon SD , et al. Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke. J Pediatr 2010; 156 (4) 651-656
• 7 Bernard TJ, Manco-Johnson MJ, Lo W , et al. Towards a consensus-based classification of childhood arterial ischemic stroke. Stroke 2012; 43 (2) 371-377